पदोन्नति कार्यक्रम Immuneering Corporation
उन्नत शेड्यूल
सरल ग्राफ
कंपनी के बारे में
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
| Выручка |
0.0019 |
| EBITDA |
-0.0073 |
| Число акций ао |
0.02842 млрд |
| P/S |
211.07 |
| P/BV |
2.81 |
| EV/EBITDA |
-0.3855 |
| Цена ао |
2.39 |
| ISIN |
US45254E1073 |
| Сайт |
https://immuneering.com
|
| Валюта |
usd |
| IPO date |
2021-07-30 |
| Sector |
Health Care |
| Industry |
Biotechnology |
| Валюта отчета |
usd |
| प्रति दिन मूल्य परिवर्तन: |
0% (2.31) |
| प्रति सप्ताह मूल्य परिवर्तन: |
+5.48% (2.19) |
| प्रति माह मूल्य परिवर्तन: |
+14.36% (2.02) |
| 3 महीने में कीमत में बदलाव: |
+102.63% (1.14) |
| छह महीने में कीमत में बदलाव: |
+28.33% (1.8) |
| प्रति वर्ष मूल्य परिवर्तन: |
-61.5% (6) |
| 3 वर्षों में मूल्य परिवर्तन: |
-92.06% (29.11) |
| वर्ष की शुरुआत से मूल्य परिवर्तन: |
-70.72% (7.89) |
|
|
बहुत मूल्यवान समझना
| नाम |
अर्थ |
श्रेणी |
| P/S |
467155.72 |
1 |
| P/BV |
2.35 |
6 |
| P/E |
0 |
0 |
| EV/EBITDA |
-2.73 |
0 |
| कुल: |
|
3.5 |
|
क्षमता
| नाम |
अर्थ |
श्रेणी |
| ROA, % |
-52.12 |
0 |
| ROE, % |
-59.03 |
0 |
| कुल: |
|
0 |
|
|
|
लाभांश
| नाम |
अर्थ |
श्रेणी |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| कुल: |
|
0 |
|
कर्तव्य
| नाम |
अर्थ |
श्रेणी |
| Debt/EBITDA |
-0.0774 |
10 |
| कुल: |
|
8.6 |
|
विकास का आवेग
| नाम |
अर्थ |
श्रेणी |
| लाभप्रदता Revenue, % |
-99.98 |
0 |
| लाभप्रदता Ebitda, % |
695.35 |
10 |
| लाभप्रदता EPS, % |
100.27 |
10 |
| कुल: |
|
8 |
|
| पर्यवेक्षक |
नौकरी का शीर्षक |
भुगतान |
जन्म का साल |
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. |
Co-Founder, President, CEO & Director |
935.09k |
1983 (41 वर्ष) |
| Dr. Brett M. Hall Ph.D. |
Chief Scientific Officer |
905.41k |
1969 (55 साल) |
| Ms. Mallory Morales CPA |
Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer |
N/A |
1984 (40 साल) |
| Ms. Paula George CPA |
Director of Accounting & Operations and Assistant Corporate Controller |
N/A |
|
| Mr. Michael D. Bookman J.D. |
Chief Legal Officer & Secretary |
N/A |
1987 (37 साल) |
| Ms. Leah R. Neufeld |
Chief People Officer |
N/A |
1973 (51 वर्ष) |
| Dr. Peter King Ph.D. |
Head of Discovery & VP |
N/A |
|
| Dr. Praveen Nair Ph.D. |
Head of Translational Pharmacology & VP |
N/A |
|
| Mr. Harold E. Brakewood |
Chief Business Officer |
579.77k |
1966 (58 साल) |
| Mr. Robert J. Carpenter M.B.A., M.S. |
Co-Founder & Chair Emeritus |
75.36k |
1946 (78 साल) |
